Amarna Therapeutics is a privately held European biotechnology company developing a next-generation viral vector platform that could play a key role in transforming treatment across many disease areas.
Amarna's next-generation viral vector platform promises to transform treatment across many disease areas.
Amarna Therapeutics was founded in 2008 by Ben van Leent & Peter de Haan. The company is headquartered in Leiden, the Netherlands, with R&D and production facilities in the Netherlands and Spain.
Amarna is the first company to successfully develop SVac, a viral vector platform derived from the simian polyomavirus 40 (SV40). Amarna produces SVac vector particles using its proprietary SuperVero producer cell line.
Amarna has genetically engineered the SV40 genome used for the production of vector particles and in parallel generated a novel Vero-based packaging cell line named SuperVero that produces similar numbers of vector particles to the currently used packaging cell lines but without contaminating wild type SV40 particles.
Amarna Therapeutics is backed by Flerie Invest AB, Netherlands Enterprise Agency, and Pim Berger, an existing shareholder. The company raised €10M from a latest financing on Oct 16, 2019. This brings Amarna's total funding to €21.1M to date.